

DAFTAR PUSTAKA

1. Gaol HL, Mochtar CA. Hiperplasia Prostat Jinak. dalam: Tanto C, Liwang F, Hanifati S, Pradipta, EA, editor. Kapita Selekta Kedokteran. edisi ke-4 jilid 1. Jakarta:FK-UI; 2016. hh. 284-287.
2. Parsons JP, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. *The Journal of Urology*. 2020; 204: 799.
3. Cho A, Chughtai, B, Te AE. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. *Current Bladder Dysfunction Reports*. 2020;15(2): 60-65.
4. Lim K. Epidemiology of Clinical Benign Prostatic Hyperplasia. *Asian Journal of Urology*. 2017;4(3):148-151.
5. Wang W, Guo Y, Zhang D, Tian Y, Zhang X. The Prevalence of Benign Prostatic Hyperplasia in Mainland China: Evidence from Epidemiological Surveys. *Scientific Reports*. 2015;5(1).
6. Ng Michael, Baradhi K. Benign Prostatic Hyperplasia. *Treasure Island (FL): StatPearls [Internet]*; 2020.
7. Tjahjodjati, Soebadi DM, Umas R, Purnomo BB, Widjanarko S, Mochtar CA, dkk. Panduan Penatalaksanaan Klinis Pembesaran Prostat Jinak (*Benign Prostatic Hyperplasia/BPH*). edisi ke-3. Ikatan Ahli Urologi Indonesia; 2017.
8. Khomeini, Efmansyah D, Erkadius. Hubungan Penurunan Kadar Natrium terhadap Gangguan Pola Tidur pasca TURP (*Transurethral Resection of the Prostate*). *Jurnal Kesehatan Andalas*. 2013;2(1):9-13
9. Umbas R. Saluran Kemih dan Alat Kelamin Lelaki. dalam: Sjamsuhidajat R, Karnadihardja W, Prasetyono TOH, Rudiman R, editor. Buku Ajar Ilmu Bedah Sjamsuhidajat-de Jong. edisi ke-3. Jakarta: Penerbit Buku Kedokteran EGC; 2010. hh. 899-902.
10. Bortnick E, Brown C, Simma-Chiang V, Kaplan S. Modern Best Practice in the Management of Benign Prostatic Hyperplasia in the Elderly. *Therapeutic Advances in Urology*. 2020;12:1-11.
11. Setiawati A, Gan S. Penghambat Adregenik. Dalam: Farmakologi dan Terapi. Edisi 5. Jakarta: Balai Penerbit FKUI. 2012. hal. 85-104.
12. Duan Y, Grady J, Albertsen P, Helen Wu Z. Tamsulosin and the Risk of Dementia in Older Men with Benign Prostatic Hyperplasia. *Pharmacoepidemiology and Drug Safety*. 2018;27(3):340-348.
13. Narayan P, Tunuguntla HS. Long-term Efficacy and Safety of Tamsulosin for Benign Prostatic hyperplasia. *Rev Urol*. 2005;7 Suppl 4:S42-8. Welliver C, Butcher M, Potini Y, McVary K. Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function. *Current Urology Reports*. 2014;15(10).

14. Song S, Son H, Kim K, Kim S, Moon D, Moon K et al. Effect of tamsulosin on ejaculatory function in BPH/LUTS. *Asian Journal of Andrology*. 2011;13(6):846-850.
15. Choi J, Hwa J, Kam S, Jeh S, Hyun J. Effects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia. *The World Journal of Men's Health*. 2014;32(2):99.
16. Washington III SL, Shinohara K. Disorders of the Bladder, Prostate, and Seminal Vesicles. In: Smith and Tanagho's General Urology. 19th ed. New York : Lange Medical Book/McGraw-Hill; 2020. p. 585-604
17. Roehrborn CG. Pathology of Benign Prostatic Hyperplasia. *International Journal of Impotence Research*. 2008;20(S3):S11-S18
18. Egan K. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms. *Urologic Clinics of North America*. 2016;43(3):289-297. Nachawati D, Patel J. Alpha Blockers. Treasure Island (FL). StatPearls [Internet]; 2020.
19. McNicholas T, Mitchell S. Benign Prostatic Hyperplasia. *Medical Progress*. 2009;36(4):178-183.
20. Fibbi B, Penna G, Morelli A, Adorini L, Maggi M, review article: Chronic Inflammation in the Pathogenesis of Benign Prostatic Hyperplasia. *International Journal of Andrology*. 2010;33:475-488.
21. Sabiston. *Buku Ajar Bedah*. jilid 2. Jakarta: Penerbit Buku Kedokteran EGC; 1994. hh. 479.
22. Parsons JK, Kashefi C. Physical Activity, Benign Prostatic Hyperplasia, and Lower Urinary Tract Symptoms. *European Urology*. 2008;53:1228-1235.
23. Nachawati D, Patel J. Alpha Blockers. Treasure Island (FL). StatPearls [Internet]; 2020.
24. Food and Drug Administration (US). Highlights of Prescribing Information Flomax (tamsulosin hydrochloride) Capsules, 0.4 mg. Washington D.C.:U.S. Food and Drug Administration; 2009.
25. Lepor H. The Evolution of Alpha-blockers for the Treatment of benign prostatic hyperplasia. *U.S. National Library of Medicine*. 2006;8(4):S3-S9.
26. Gravas S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulakis C, et al. Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO): EAU guideline. *European Association of Urology Guidelines*. 2020;1-77.
27. Torre A, Giupponi G, Duffy D, Conca A, Cai T, Scardigli A. Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α -Blocker and 5-ARI Drugs. *Pharmacopsychiatry* 2016; 49: 3–13
28. Bell CM, Hatch WV, Fischer HD, Cernat G, Paterson JM, Grunier A, et al. Association Between Tamsulosin and Serious Ophthalmic Adverse Events in Older Men Following Cataract Surgery. *JAMA*. 2009;301(19):1991-1996
29. Reynard J, Brewster S, Biers S, Neal N. Bladder Outlet Obstruction. In: Reynard J, Brewster S, Biers S, Neal N. *Oxford Handbook of Urology*. 4th ed. United Kingdom: Oxford University Press; 2018. p. 71-127
30. Bird S, Delsney J, Brophy J, Etminan M, Skeldon S, Hartzema A. Tamsulosin Treatment for Benign Prostatic Hyperplasia and risk of severe hypotension in men ages 40-85 Years in United States: Risk Window

Analyses using between and within Patient Methodology. *BMJ*. 2013;347(Nov 05 3):f6320-f6327.

31. Kim DY, Chung TH, Kim SJ, Kim JH, et al. Association between Benign Prostate Hyperplasia and Occupational Group. *Korean J Fam Pract*. 2019;9(2):196-203
32. Xiong Y, Zhang Y, Li X, Qin F, Yuan J. The prevalence and associated factors of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males. *The Aging Male*. 2020;23(5):1432-1439.
33. Khattak B, Khan ZU, Khan RA. Evaluation of Erectile Dysfunction and Retrograde Ejaculation in Patients with Benign Prostatic Hyperplasia Receiving Combined Drug Therapy. *J Postgrad Med Inst* 2020; 34(1): 59-63.
34. Choi H, Sim J, Park J, Bae J. Assessment of Tamsulosin 0.2 mg for Symptomatic Bladder Outlet Obstruction Secondary to Benign Prostatic Enlargement: Data from a Korean Multicenter Cross-Sectional Study. *Urologia Internationalis*. 2015;95(1):50-55.
35. Fritschi L, Glass D, Tabrizi J, Leavy J, et al. Occupational risk factors for prostate cancer and benign prostatic hyperplasia: a case-control study in Western Australia. *Occupational and Environmental Medicine*. 2006;64(1):60-65.
36. Lagiou A, Samoli E, Georgila C, Minaki P, et al. Occupational physical activity in relation with prostate cancer and benign prostatic hyperplasia. *European Journal of Cancer Prevention*. 2008;17(4):336-339.
37. Pramana I, Oka A, Duarsa G, Santosa K, et al. The effectiveness of tamsulosin in Benign Prostate Hyperplasia (BPH) patients with Lower Urinary Tract Symptoms (LUTS): a multi-centre cohort retrospective study. *Indonesia Journal of Biomedical Science*. 2020;14(1):17.
38. Gandhi J, Weissbart S, Smith N, Kaplan S, et al. The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. *Translational Andrology and Urology*. 2017;6(2):295-304.
39. Goktas S, Kibar Y, Kilic S, Topac H, Coban H, et al. Recovery of Abnormal Ejaculation by Intermittent Tamsulosin Treatment. *Journal of Urology*. 2006;175(2):650-653.
40. Revenig L, Leung A, Hsiao W. Ejaculatory Physiology and Pathophysiology: Assessment and Treatment in Male Infertility. *Transl Androl Urol* 2014;3(1):41-49
41. Grasso M, Fortuna F, Lania C, Blanco S. "Ejaculatory disorders and α 1-adrenoceptor antagonists therapy: clinical and experimental researches". *Journal of Translational Medicine*. 2006;4(1).
42. Stojanovic N, Ignjatovic I, Djenic N, Bogdanovic D. Adverse Effects of Pharmacological Therapy of Benign Prostatic Hyperplasia on Sexual Function in Men. *Srpski arhiv za celokupno lekarstvo*. 2015;143(5-6):284-289.
43. Yanardag H, Goktas S, Kibar Y, Kilic S et al. Intermittent Tamsulosin Therapy in Men with Lower Urinary Tract Symptoms. *Journal of Urology*. 2005;173(1):155-157.